General MedicationsINTRAVENOUSStandard
FYARRO
SIROLIMUS
Standard Dose
100MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview FYARRO is listed in Drugs@FDA under application 213312 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient SIROLIMUS Form and strength POWDER;INTRAVENOUS - 100MG/VIAL Sponsor AADI SUB Submission history Latest submission status date: 2021-11-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview FYARRO is listed in Drugs@FDA under application 213312 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient SIROLIMUS Form and strength POWDER;INTRAVENOUS - 100MG/VIAL Sponsor AADI SUB Submission history Latest submission status date: 2021-11-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.